
Carl Zeiss Meditec Group





Sebastian Frericks, CFAHead of Group Finance & Investor Relations

ZEISS Medical Technology <10 Seconds
of lypproving
of lypproving
quality of life








Carl Zeiss Meditec Has A Track Record of Strong Profitable Growth





€1.9 billion Revenue

Long-term growth trend over 20 years

~20.9% EBIT margin in FY 2021/22

Reasons to invest




1 Innovation

3 Asia/Pacific

2 Recurring Revenue

4 Digitalization



ZEISS

1st Neuro Microscope





1st oct





1st Biometer White the second of the second



1st company

to develop trifocal intraocular lenses





1st company

to develop minimally invasive laser surgery



Growing share of Recurring Revenue



Share of recurring revenue has advanced steadily over two decades







Have been performed since the launch in 2011







Digitalization – ZEISS Medical Ecosystem





Reasons to invest



1 Innovation

3 Asia/Pacific

2 Recurring Revenue

4 Digitalization

Outlook





Growth ahead of our markets



> 20% sustainable mid-term EBIT margin



Sebastian Frericks, CFA

Head of Group Finance & Investor Relations

Phone: +49 (0) 36 41 / 2 20 - 1 16

Fax: +49 (0) 36 41 / 2 20 - 1 17

Email: investors.meditec@zeiss.com

Web: www.zeiss.com/meditec-ag/investor-relations



Seeing beyond